Revolution Medicines, Inc. (RVMD)

Market Cap	2.28B
Revenue (ttm)	35.38M
Net Income (ttm)	-248.71M
Shares Out	106.17M
EPS (ttm)	-3.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	506,527
Open	21.61
Previous Close	21.52
Day's Range	21.11 - 22.19
52-Week Range	14.08 - 31.37
Beta	1.49
Analysts	Buy
Price Target	32.51 (+51.35%)
Earnings Date	May 8, 2023

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 13, 2020
• Employees: 239
• Stock Exchange: NASDAQ
• Ticker Symbol: RVMD

Financial Performance

In 2022, RVMD's revenue was $35.38 million, an increase of 20.38% compared to the previous year's $29.39 million. Losses were -$248.71 million, 32.9% more than in 2021.

Analyst Forecast

According to 16 analysts, the average rating for RVMD stock is "Buy." The 12-month stock price forecast is $32.51, which is an increase of 51.35% from the latest price.

Price Target

$32.51

(51.35% upside)

Analyst Consensus: Buy